- Home
- BTAI vs ATHA Comparison
BTAI vs ATHA Comparison
Compare BTAI & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- ATHA
- Stock Information
- Founded
- BTAI 2017
- ATHA 2011
- Country
- BTAI United States
- ATHA United States
- Employees
- BTAI N/A
- ATHA N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- BTAI Health Care
- ATHA Health Care
- Exchange
- BTAI Nasdaq
- ATHA Nasdaq
- Market Cap
- BTAI 18.1M
- ATHA 21.0M
- IPO Year
- BTAI 2018
- ATHA 2020
- Fundamental
- Price
- BTAI $0.34
- ATHA $0.53
- Analyst Decision
- BTAI Buy
- ATHA Buy
- Analyst Count
- BTAI 4
- ATHA 4
- Target Price
- BTAI $2.81
- ATHA $11.25
- AVG Volume (30 Days)
- BTAI 1.3M
- ATHA 235.4K
- Earning Date
- BTAI 03-11-2025
- ATHA 02-20-2025
- Dividend Yield
- BTAI N/A
- ATHA N/A
- EPS Growth
- BTAI N/A
- ATHA N/A
- EPS
- BTAI N/A
- ATHA N/A
- Revenue
- BTAI $2,276,000.00
- ATHA N/A
- Revenue This Year
- BTAI $131.23
- ATHA N/A
- Revenue Next Year
- BTAI $45.79
- ATHA N/A
- P/E Ratio
- BTAI N/A
- ATHA N/A
- Revenue Growth
- BTAI 83.25
- ATHA N/A
- 52 Week Low
- BTAI $0.30
- ATHA $0.41
- 52 Week High
- BTAI $4.17
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- BTAI 42.14
- ATHA 41.88
- Support Level
- BTAI $0.33
- ATHA $0.52
- Resistance Level
- BTAI $0.39
- ATHA $0.57
- Average True Range (ATR)
- BTAI 0.06
- ATHA 0.04
- MACD
- BTAI -0.00
- ATHA -0.00
- Stochastic Oscillator
- BTAI 9.27
- ATHA 11.82
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.